Chunmei Liu

Over-Expression of EFNA2 in Lung Adenocarcinoma: EFNA2 Gene Expression Correlates with Shortened Survival

Chunmei Liu, Yanjiao Wu, Huandi Zhou, Xiaohui Ge, Xiaojing Chang, Guohui Wang & Xiaoying Xue · Journal of Pharmaceutical Research International · 2024

Background: The incidence of lung adenocarcinoma (LUAD) is increasing worldwide with different prognosis. Ephrin-A2（EFNA2), a member of the Eph/ephrin family, is associated with tumor progression. However, the correlations of EFNA2 with prognosis in LUAD remain unclear. The   pu...

Open access Research Article 10.9734/jpri/2024/v36i37503

A Phase II Open-Label Multi-center Trial of Isotoxic Hypofractionated Radiotherapy for NSCLC

Chunmei Liu, Qiang Lin, Huandi Zhou, Xiaohui Ge, Chaoxing Liu, Dongxue Gao, Yufeng Zhang & Xiaoying Xue · Journal of Pharmaceutical Research International · 2022

Background: The standard treatment for advanced unresectable non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy. However, many poor Karnofsky score or elderly patients cannot tolerate it due to heir serious side effects. For patients who cannot tolerate concurrent...

Open access Research Article 10.9734/jpri/2022/v34i32A36102